HCWB
NASDAQHCW Biologics Inc.
Price$1.15-0.02 (-2.14%)
01:45 PM07:30 PM
News · 26 weeks56-35%
2025-12-212026-06-14
Mix3590d
- SEC Filings19(54%)
- Other11(31%)
- Insider3(9%)
- Dividends2(6%)
Latest news
25 items- SECHCW Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - HCW Biologics Inc. (0001828673) (Filer)
- PRHCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia AreataPotentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells Readout for dose-escalating clinical study for first two dose cohorts All participants in second dose cohort at the dose level of 3 micrograms/kg body weight showed positive clinical response after single dose administration Well tolerated, with no dose-limiting toxicities or significant known IL-2-treatment-related adverse effects, including no reported incidence of capillary leak, cytokine release syndrome, or increase in blood eosinophil counts HCW Biologics projects to establish the Recommended Phase 2 Dose by year end 2026 MIRAMAR, Fla., June 16, 2026 (GLOBE NEWSW
- SECHCW Biologics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - HCW Biologics Inc. (0001828673) (Filer)
- SECSEC Form D filed by HCW Biologics Inc.D - HCW Biologics Inc. (0001828673) (Filer)
- SECSEC Form S-1 filed by HCW Biologics Inc.S-1 - HCW Biologics Inc. (0001828673) (Filer)
- SECHCW Biologics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - HCW Biologics Inc. (0001828673) (Filer)
- INSIDERChief Executive Officer Wong Hing C bought $160,000 worth of shares (113,879 units at $1.41), increasing direct ownership by 23% to 615,790 units (SEC Form 4)4 - HCW Biologics Inc. (0001828673) (Issuer)
- INSIDERDirector Garrett Scott T bought $250,000 worth of shares (177,936 units at $1.41) (SEC Form 4)4 - HCW Biologics Inc. (0001828673) (Issuer)
- INSIDERChief Financial Officer Byam Rebecca bought $20,000 worth of shares (14,235 units at $1.41), increasing direct ownership by 33% to 57,245 units (SEC Form 4)4 - HCW Biologics Inc. (0001828673) (Issuer)
- SECHCW Biologics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits8-K - HCW Biologics Inc. (0001828673) (Filer)
- PRHCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from WugenPositions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies, with the potential to support curative outcomes Company plans to commercialize the reagents through corporate partners focused on CAR-T and NK-cell therapies, including developers and manufacturers MIRAMAR, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing first-in-class fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia, today announced t
- PRE.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private PlacementNEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the sole placement agent in connection with a $4.0 million private placement for HCW Biologics Inc. ("HCW Biologics" or the "Company") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics designed to treat diseases driven by chronic inflammation, including autoimmune disorders, cancer, and senescence-associated conditions. Joseph T. Rallo, Chief Executive Officer of E.F. Hutton & Co., commented, "We are pleased to have partnered with HCW Biolo
- SECHCW Biologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - HCW Biologics Inc. (0001828673) (Filer)
- PRHCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq RulesMIRAMAR, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune, cancer and senescence-associated dysplasia, today announced the pricing of its private placement of an aggregate of 2,846,975 units at a purchase price of $1.405 per unit priced at-the-market under Nasdaq rules to a group of healthcare investors (the "Investors"). Each unit consists of (i) one share of common stock at a purchase price of $1.28 per share (or, in lieu thereof, one pre-funded warrant at a purchase price of $1.2799 per pre-funded warrant with an e
- SECSEC Form POS AM filed by HCW Biologics Inc.POS AM - HCW Biologics Inc. (0001828673) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by HCW Biologics Inc.SCHEDULE 13G/A - HCW Biologics Inc. (0001828673) (Subject)
- PRBiologics Market Momentum Accelerates Across Healthcare, AI, And Global Medical TourismDENVER, May 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) - The biologics sector is rapidly emerging as one of the most closely watched growth stories in healthcare as breakthroughs in immunotherapy, regenerative medicine, cell engineering, and AI-assisted drug development continue reshaping investor sentiment. Unlike traditional pharmaceutical compounds, biologics leverage complex biological systems to target diseases with greater specificity, opening new opportunities in cancer, autoimmune disorders, rare diseases, and regenerative therapies. The investment narrative around biologics has expanded far beyond drug development alone. Today, the sector sits at the intersection of artific
- SECSEC Form 10-Q filed by HCW Biologics Inc.10-Q - HCW Biologics Inc. (0001828673) (Filer)
- SECHCW Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - HCW Biologics Inc. (0001828673) (Filer)
- PRHCW Biologics Reports First Quarter 2026 Business Highlights and Financial ResultsMIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune disease, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three months ended March 31, 2026. The Company remains on track to provide preliminary clinical data readout from the first two dose levels of the Phase 1 clinical study evaluating HCW9302 in alopecia areata in the first half of 2026. There are two clinical sites actively enrolling patients, and enrollment has been on schedule.
- PRHCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling StudiesHCW11-040 is a pembrolizumab-based fusion immunotherapeutic that activates immune cells and eliminates high-oxygen induced senescent cells BPD is a rare pediatric disease affecting underweight premature infants which the Company believes aligns with newly reauthorized rare pediatric disease and review voucher programs BPD causes abnormal lung development in premature infants that leads to long-term health problems that persist into adulthood as well as neurodevelopmental delays MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immun
- SECSEC Form POS AM filed by HCW Biologics Inc.POS AM - HCW Biologics Inc. (0001828673) (Filer)
- SECHCW Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - HCW Biologics Inc. (0001828673) (Filer)
- PRHCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of QuorumMIRAMAR, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation today announced that the Company's Special Meeting of Stockholders, held on April 27, 2026, at 10:00 a.m. Eastern Time ("Special Meeting") was adjourned, without any business being conducted, due to lack of the required quorum and the matters were adjourned to the Annual Meeting of Stockholders. The proposals presented to stockholders for their consideration at the Special Meeting will be included in the proposals pr
- SECSEC Form EFFECT filed by HCW Biologics Inc.EFFECT - HCW Biologics Inc. (0001828673) (Filer)
HCWB FAQ
6 questionsWhere does HCWB stock trade?
HCW Biologics Inc. (HCWB) is listed on NASDAQ.What sector and industry is HCWB in?
HCW Biologics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did HCW Biologics Inc. go public?
HCW Biologics Inc. (HCWB) completed its IPO in 2021.What are analysts saying about HCWB?
HCW Biologics Inc. has had 1 recent analyst action on file. The most recent action was from EF Hutton: Buy with a $1000.00 price target on 2021-11-19. Recent price targets cluster around $1000.00.What companies are similar to HCWB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare HCWB side-by-side with any of them on Quantisnow.How can I track HCWB on Quantisnow?
Quantisnow aggregates HCW Biologics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HCWB to receive live email and push alerts on every new disclosure.